羅欣藥業(yè)宣布與JW Holdings簽署第三代三腔袋全腸外營養(yǎng)品獨(dú)家開發(fā)協(xié)議

發(fā)布時間：2020年10月26日 瀏覽次數(shù)：

分享：

羅欣藥業(yè)集團(tuán)股份有限公司（股票代碼002793，簡稱“羅欣藥業(yè)”）子公司山東羅欣藥業(yè)集團(tuán)股份有限公司今天上午通過云簽約方式與韓國醫(yī)藥企業(yè)JW Holdings在線簽署合作協(xié)議。針對JW Holdings旗下第三代三腔袋全腸外營養(yǎng)品Winuf?，JW Holdings將授予羅欣藥業(yè)在中國內(nèi)地、香港特別行政區(qū)、澳門特別行政區(qū)開發(fā)和商業(yè)化該產(chǎn)品的獨(dú)家權(quán)益。目前中國國內(nèi)尚無含魚油三腔袋全腸外營養(yǎng)品上市。據(jù)悉，JW Holdings為歐洲GMP認(rèn)證的首個亞洲該類產(chǎn)品生產(chǎn)廠家。

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. , subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. (Stock Code: 002793, hereinafter referred to as "Luoxin Pharmaceutical"), signed an exclusive license and distribution agreement with JW Holdings through an online ceremony this morning. The agreement grants Luoxin Pharmaceutical the exclusive right to develop and commercialize Winuf? under JW Holdings in the Chinese mainland, Hong Kong and Macau. Winuf? is a three-chamber total parenteral nutrition (TPN) product and so far there are no commercialized TPN products containing refined fish oil on the Chinese market. Besides, JW Holdings is the first Asian TPN manufacturer certified by European GMP.

在線簽約儀式現(xiàn)場

Winuf?于2013年在韓國上市，并已經(jīng)進(jìn)入歐洲市場。該產(chǎn)品含多種脂類物質(zhì)、葡萄糖及氨基酸，適用于無法通過腸內(nèi)途徑攝取營養(yǎng)的患者、大劑量放化療營養(yǎng)不良患者、嚴(yán)重消化功能障礙患者等人群。其精制魚油含量超過其他已上市三腔袋全腸外營養(yǎng)品規(guī)，可促進(jìn)肝功能改善、促進(jìn)人體脂代謝、有效抗炎并促進(jìn)患者免疫力提升與恢復(fù)。該產(chǎn)品去年在韓國國內(nèi)銷售額突破557億韓元；據(jù)IQVIA數(shù)據(jù)顯示，全球三腔袋全腸外營養(yǎng)品市場份額增長迅速，2017-2019年全球市場年均增長率達(dá)到9.1%，中國市場年均增長率達(dá)到25.5%。

Launched in South Korea in 2013, Winuf? has also entered the European market. It consists of 4 lipid components, as well as glucose and amino acids. It’s suitable for patients who are not capable of enteral nutrition feeding, for malnutrition patients under high-dose radiotherapy or chemotherapy, and for patients with severe digestive dysfunction, etc. Winuf? contains a higher content of refined fish oil than other existing products, and promotes the improvement and recovery of immunity in patients. The domestic sales of Winuf? in South Korea were recorded as KRW 55.7 billion last year. According to IQVIA, the three-chamber TPN market is growing rapidly, with the average growth rate over the three years (2017-2019) of 9.1% globally and 25.5% in China.

根據(jù)協(xié)議條款，羅欣藥業(yè)將承擔(dān)Winuf?在中國境內(nèi)的臨床研究、注冊和商業(yè)化相關(guān)活動。JW Holdings將獲得預(yù)付款，負(fù)責(zé)產(chǎn)品制造、供應(yīng)，并按中國未來產(chǎn)品銷售額獲得相關(guān)里程碑付款和特許使用權(quán)費(fèi)用。JW Holdings首席執(zhí)行官Sung Kwon Han表示：“我們相信羅欣藥業(yè)的臨床研究和商業(yè)化平臺能夠幫助我們將Winuf?順利引進(jìn)中國市場。我們也希望借此契機(jī)將Winuf?推向全球市場，并期待未來與羅欣藥業(yè)拓展更多合作空間?！?/p>

According to the terms of the agreement, Luoxin Pharmaceutical will undertake the clinical research, registration and commercialization of Winuf? in China. JW Holdings will receive the upfront payment, be responsible for product manufacturing and supply of Winuf?, and obtain sales milestone and tiered-royalties from Luoxin Pharmaceutical based on future sales in China. “We believe that Luoxin Pharmaceutical's platform of clinical research and commercialization can help us successfully introduce Winuf? into the Chinese market. We also hope to take this opportunity to promote the global opportunities of our product, and look forward to expanding our cooperation with Luoxin Pharmaceutical in the future, "said Sung Kwon Han, CEO of JW Holdings.

“我們很高興與JW Holdings達(dá)成此項合作協(xié)議，也期待相關(guān)產(chǎn)品盡快進(jìn)入中國市場并造福相關(guān)適應(yīng)癥患者?！?羅欣藥業(yè)董事長劉振騰表示，“公司近年來與多家韓國企業(yè)合作，攜手促進(jìn)多種優(yōu)秀的產(chǎn)品和療法進(jìn)入中國。我們將繼續(xù)堅持自主與合作研發(fā)的雙軌模式，打造更多能夠經(jīng)受市場考驗的潛力管線，為客戶、病患和社會各界創(chuàng)造最大的所需價值空間！”

"We are very pleased to reach agreement with JW Holdings. We hope Winuf? will enter the Chinese market and benefit patients with relevant indications as soon as possible," said Ryan Liu, CEOof Luoxin Pharmaceutical. "In recent years, Luoxin Pharmaceutical has formed strategic partnerships with many Korean enterprises to introduce excellent products and therapies into China. We will attach equal importance to independent and cooperative R&D, create pipeline that can withstand the market test, and bring more value to customers, patients and the society! "

關(guān)于JW Group

JW集團(tuán)自1945成立以來，一直以尊重生命和創(chuàng)新精神為理念拓展制藥研發(fā)，引領(lǐng)韓國本土市場，并于1959年開啟韓國首個“5%葡萄糖”醫(yī)院解決方案。

其旗艦子公司JW Pharmaceutical擁有包括抗癌藥物在內(nèi)的各種創(chuàng)新藥研發(fā)渠道。JW Life Science則是一家專門從事醫(yī)用注射劑生產(chǎn)的子公司，每年生產(chǎn)和供應(yīng)800萬種綜合營養(yǎng)素，該公司也擁有全球最大的環(huán)保非PVC醫(yī)用注射劑工廠。

JW控股除管理子公司之外，還直接負(fù)責(zé)集團(tuán)原材料、藥品和醫(yī)療器械的海外業(yè)務(wù)。JW Holdings在韓國交易所上市，股票代碼為“096760”。

About JW Group

JW Group has been leading the Korean market for therapeutic drugs based on respect for life and the founding philosophy of pioneering spirit since its foundation in 1945. In 1959, the nation's first medical hospital solution, "5% glucose," has started its local manufacture.

JW Pharmaceutical, its flagship subsidiary, has various innovative new drug R&D pipelines, including anti-cancer drugs, while JW Life Science, a subsidiary specializing in hospital injection production, produces and supplies 8 million comprehensive nutrients annually based on the world's largest plant dedicated to eco-friendly Non-PVC hospital injections.
 JW Holdings is also directly responsible for overseas business of raw materials, drugs and medical devices in the group, in addition to managing subsidiaries, generating profits. JW Holdings is listed on the Korean exchange as '096760'.

 關(guān)于羅欣藥業(yè)

羅欣藥業(yè)集團(tuán)股份有限公司（以下簡稱“羅欣藥業(yè)”）是集藥品研發(fā)、生產(chǎn)、貿(mào)易及醫(yī)療健康服務(wù)為一體的大型醫(yī)藥企業(yè)集團(tuán)。躋身發(fā)展速度領(lǐng)先的中國制藥企業(yè)方陣，羅欣藥業(yè)致力于為客戶提供高品質(zhì)原料藥、多劑型藥物（片劑、膠囊劑、注射劑等）和醫(yī)療健康服務(wù)。

羅欣藥業(yè)連續(xù)多年位列中國制藥工業(yè)百強(qiáng)企業(yè)榜單，且多次被評為“制藥企業(yè)研發(fā)實力20強(qiáng)”，已于2019年登陸中國A股市場，股票代碼002793。

About Luoxin Pharmaceutical

Luoxin Pharmaceutical Group Stock Co., Ltd. is a healthcare conglomerate corporation in China that is engaged in pharmaceutical research and development, manufacture, sales, and healthcare service. As one of the fastest growing pharmaceutical companies in China, it serves customers with high quality active pharmaceutical ingredients (APIs), finished products in various formulation forms (tablets, capsules, injectable, etc.), and healthcare service.

Now the company has been ranking top 100 of China's Pharmaceutical Industry in terms of overall competence nationwide, and identified as one of the “Top 20 Pharmaceutical Companies with Strong R&D Pipelines” for years. The company was listed on China's A-shares market in 2019 as ‘002793’.